Preclinical News and Research

RSS
X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Symphogen closes €100 million stock to a group of investors

Symphogen closes €100 million stock to a group of investors

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Transposagen, CDI enter license agreement for iPS cell line production

Transposagen, CDI enter license agreement for iPS cell line production

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

arGEN-X's alliance with Lilly highlights potential of SIMPLE Antibody platform

arGEN-X's alliance with Lilly highlights potential of SIMPLE Antibody platform

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Researchers create model that predicts drug effects on fetal development

Researchers create model that predicts drug effects on fetal development

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia

FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.